Christian Pellevoisin

Dr. Christian Pellevoisin


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MBMichel Bataillon
Michel Bataillon
DLDamien Lelièvre
Damien Lelièvre
ACAdeline Chapuis
Adeline Chapuis
FTFabienne Thillou
Fabienne Thillou
JAJean Baptiste Autourde
Jean Baptiste Autourde
CPChristian Pellevoisin
Christian Pellevoisin
Background: We have characterized a new reconstructed full-thickness skin model, T-Skin™, compared to normal human skin (NHS) and evaluated its use in testing anti-aging compounds. Methods: The structure and layer-specific markers were compared with NHS using histological and immunohistological staining. In anti-aging experiments, T-SkinTM was exposed to retinol (10 µM) or vitamin C (200 µM) for 5 days, followed by immunohistological staining evaluation. Results: T-Skin™ exhibits a well stratified, differentiated and self-renewing epidermis with a dermal compartment of functional fibroblasts. Epidermal (cytokeratin 10, transglutaminase 1), dermo–epidermal junction (DEJ) (laminin 5, collagen-IV, collagen VII) and dermally-located (fibrillin 1, procollagen I) biomarkers were similar to those in NHS. Treatment of T-Skin™ with retinol decreased the expression of differentiation markers, cytokeratin 10 and transglutaminase 1 and increased the proliferation marker, Ki67, in epidermis basal-layer cells. Vitamin C increased the expression of DEJ components, collagen IV and VII and dermal procollagen 1. Conclusions: T-Skin™ exhibits structural and biomarker location characteristics similar to NHS. Responses of T-Skin™ to retinol and vitamin C treatment were consistent with those of their known anti-aging effects. T-Skin™ is a promising model to investigate responses of epidermal, DEJ and dermal regions to new skin anti-ageing compounds.

1 August 2018 in Toxicology in Vitro
Verified
Journal Article
Open access
CPChristian Pellevoisin
Christian Pellevoisin
CVChristelle Videau
Christelle Videau
DBDamien Briotet
Damien Briotet
CGCorinne Grégoire
Corinne Grégoire
CTCarine Tornier
Carine Tornier
NSNathalie Seyler
Nathalie Seyler
According to ISO 10993 standards for biocompatibility of medical devices, skin irritation is one of the three toxicological endpoints to be always addressed in a biological risk assessment. This work presents a new protocol to assess this endpoint in vitro rather than in vivo. The protocol was adapted to medical devices extracts from the OECD TG 439 with the SkinEthic™ RHE model as test system. It was challenged with irritant chemicals, Sodium Dodecyl Sulfate, Lactic Acid and Heptanoic Acid spiked in polar solvents, sodium chloride solution or phosphate buffer saline and non-polar solvent, Sesame Oil. Cell viability measured by MTT reduction after 24 h exposure was used as readout. Quantification of IL-1α release as secondary readout did not increased performance. Samples of heat-pressed polyvinyl chloride (PVC) and silicone sheets infused with or without known irritant (4% Genapol-X80, 6% Genapol-X100 and 15% SDS) were tested after extraction in polar and non-polar solvents. Medical device extracts are classified irritant when the cell viability is inferior or equal to 50%, compared to the negative controls tissues, in at least one extraction solvent. The correct classification of all the samples confirmed the good performance of this new protocol for in vitro skin irritation of medical devices extracts with the SkinEthic™ RHE model. Seven naïve laboratories were trained in prevision of the Round Robin Study to evaluate Reconstructed Human Epidermis (RhE) models as in vitro skin irritation test for detection of irritant potential in medical device extracts.

1 August 2018 in Toxicology in Vitro
Verified
Journal Article
Open access
WJWim De Jong
Wim De Jong
SHSebastian Hoffmann
Sebastian Hoffmann
MLMichelle Lee
Michelle Lee
HKHelena Kandárová
Helena Kandárová
CPChristian Pellevoisin
Christian Pellevoisin
KCKelly P. Coleman
Kelly P. Coleman

26 July 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AAAna Sofia Agonia
Ana Sofia Agonia
Rita Palmeira-De-OliveiraRita Palmeira-De-Oliveira
Rita Palmeira-De-Oliveira
CCCatarina Cardoso
Catarina Cardoso
CACátia Augusto
Cátia Augusto
CPChristian Pellevoisin
Christian Pellevoisin
Rita Palmeira-De-OliveiraRita Palmeira-De-Oliveira
Rita Palmeira-De-Oliveira
The use of in vitro human skin permeation tests is of value when addressing the quality and equivalence of topical drug products in Europe and the US. Human skin is the membrane of choice for these studies. The use of human skin as a membrane is hindered by limited access, high variability of results, and limited applicability for drugs with low skin permeability. Reconstructed human epidermis (RhE) models are validated as skin surrogates for safety tests and have been explored for percutaneous absorption testing. Clotrimazole poorly permeates human skin and is widely available for topical treatments. In this study, clotrimazole creams were used to test the ability of RhE to be used as biological membrane for bioequivalence testing, based on the Draft Guideline on Quality and Equivalence of Topical Products (CHMP/QWP/708282/2018) using a discriminative and modified in vitro permeation test (IVPT). To fulfill the validation of a discriminatory method, Canesten® 10 mg/g cream was compared with a test product with the same drug strength, along with two “negative controls” dosed at a 50% and 200% drug strength. Products were compared in finite dose conditions, regarding maximal flux (Jmax) and the total amount of drug permeated (Atotal). The results showed the discriminatory power of the method among the three drug strengths with no interference of the placebo formulation. The study design and validation complied with the requirements established in the guideline for a valid IVPT. This new test system allowed for the equivalence comparison between test and comparator product. Higher permeability of the RhE compared to human skin could be observed. This arose as a strength of the model for this modified IVPT bioequivalence testing, since comparing permeation profiles among products is envisaged instead of drawing absolute conclusions on skin permeation extent. These results may support the acceptance of RhE as biological membranes for modified IVPT in bioequivalence testing of topical products.

3 March 1997 in Journal of Comparative Neurology
Verified
Journal Article
Closed access
PDF file
IAI. Aubert
I. Aubert
CBC. Brana
C. Brana
CPChristian Pellevoisin
Christian Pellevoisin
Bruno GIROSBruno GIROS
Bruno GIROS
ICIsabelle Caillé
Isabelle Caillé
BBB. Bloch
B. Bloch

17 June 1996 in Journal of Comparative Neurology
Verified
Journal Article
Closed access
PDF file
CBC. Brana
C. Brana
ICIsabelle Caillé
Isabelle Caillé
CPChristian Pellevoisin
Christian Pellevoisin
GCG. Charron
G. Charron
IAI. Aubert
I. Aubert
BBB. Bloch
B. Bloch